JPRN-UMIN000008879招募中未知
A PhaseII Study of Dose Schedule of TS-1 for Metastatic/Advanced Breast Cancer - A study of TS-1 alternate-day dosing for Breast cancer
Wakayama Medical University, Department of Thoracic and Cardiovascular Surgery0 个研究点目标入组 40 人开始时间: 2012年9月7日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)Active double cancer. 2)Watery diarrhea. 3)Require administration of flucytosine, phenytoin, and warfarin. 4)The metastases to brain which require measures for the brain hypertension and urgent brain irradiation. 5)Extensive liver metastases, or lymphatic vessel-related metastases to lung with dyspnea. 6)A lesion targeted for an evaluation is only one, and there is an enforcement history of the radiotherapy to the part. 7)Pleural effusion, ascitic fluid, pericardial effusion to need urgent treatment. 8)Severe infections being suspected. 9)Interstitial pneumonia or pulmonary fibrosis. 10)HBs antigen is positive. 11)The diabetes patients with difficult control or during treatment with insulin. 12)Serious mental disorder. 13)Pregnant woman, a nursing mother or has a hope for the pregnancy. 14)The patients who are inappropriate to the study which judged by doctors.
研究者
相似试验
已完成
2 期
Randomized phase II study of dose schedule of TS-1 for resected Colorectal CancerStage III colorectal cancerJPRN-UMIN000013185Clinical Study Group of Osaka (CSGO), Colorectal Cancer Treatment Group170
已完成
2 期
A Randomized Phase II Study of Dose Schedule of TS-1 for Metastatic/Advanced Pancreatic CancerMetastatic/Locally Advanced Pancreatic CancerJPRN-UMIN000008604Wakayama Medical University190
招募中
2 期
Phase II study of daily administration of TS-1 plus lentinan(LNT) in advanced or recurrent gastric cancer.Advanced or recurrent gastric cancerJPRN-UMIN000008590Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine50
进行中（未招募）
不适用
A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients with Severe Sepsis and Multiple Organ Dysfunction - RESPONDsevere sepsisMedDRA version: 8.1Level: LLTClassification code 10040047Term: SepsisEUCTR2006-002112-99-BEEli Lilly & Company Limited488
进行中（未招募）
1 期
A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients with Severe Sepsis and Multiple Organ Dysfunction - RESPONDEUCTR2006-002112-99-FREli Lilly & Company Limited488